Annual General Meeting of Q-Med AB (publ)

Annual General Meeting of Q-Med AB (publ) 

The Annual General Meeting of Q-Med AB (publ) was held on April 29, 2008 at 3
p.m. 

Dividend
The meeting decided that a dividend of 1.50 SEK per share shall be paid to
shareholders.

Board and fees
The meeting decided to re-elect the following members of the Board: Håkan
Edström, Bertil Hult, Anders Milton, Pia Rudengren, Åsa Rödén, Pernilla Ström
och Bengt Ågerup for the period up until the end of the next Annual General
Meeting. The meeting also re-elected Pia Rudengren as the Chair of the Board.

The meeting also decided that Board fees of 1,400,000 (1,050,000) SEK in total
be paid for the period 2007/2008, with 400,000 (300,000) SEK to the Chair of the
Board and 200,000 (150,000) SEK to each of the other members of the Board,
except for Bengt Ågerup, who is an employee of the company and shall therefore
not receive a Board fee.

Auditors' fees shall be paid in accordance with reasonable invoicing.

A fee of 200,000 (180,000) SEK in total shall be paid for work on the audit
committee, to be divided among the three members as follows: 100,000 (90,000)
SEK to the Chair of the committee and 50,000 (45,000) SEK to each of the other
two committee members.

Election committee
The majority of the election committee proposed that the election committee
shall continue to consist of three members, with Robert Wikholm as Chair with
the assignment of finding, at the latest during the third quarter, two
representatives to be included in the election committee, but with the
difference from previous years that one representative is to come from the major
owners and one is to represent the smaller shareholders. Furthermore, it was
proposed that a fee of SEK 75,000 (60,000) be paid to the election committee, to
be allocated in accordance with the decision of the election committee.

The minority of the election committee, Jan-Erik Erenius, who represents AMF
Pension, proposed an alternative procedure, which was supported by a number of
institutional owners.
The Swedish Shareholders' Association proposed a third alternative, according to
which the election committee in its entirety would be elected by the Annual
General Meeting.
A majority of the Annual General Meeting decided in accordance with the proposal
of the majority.

Principles for remuneration
Finally, the meeting decided on principles for remuneration and other conditions
of employment for senior management in accordance with the proposal of the
Board.


Queries should be addressed to:
Madelene Sandgren, Director Investor Relations and Corporate Communications 
Tel: +46 (0) 70 974 9015 

Q-Med AB is a rapidly growing and profitable biotechnology/medical device
company. The company develops, manufactures, markets, and sells primarily
medical implants. The majority of the products are based on the company's
patented technology, NASHA™, for the production of stabilized non-animal
hyaluronic acid. The product portfolio today contains: Restylane® for filling
lines and folds, contouring and creating volume in the face, Macrolane™ for body
contouring, Durolane™ for the treatment of osteoarthritis of the hip and knee
joints, Deflux® for the treatment of vesicoureteral reflux, VUR, (a malformation
of the urinary bladder) in children, and Solesta™ for the treatment of fecal
incontinence. Sales are made through the company's own subsidiaries or
distributors in over 70 countries. Q Med today has just over 700 coworkers, with
close to 500 at the company's head office and production facility in Uppsala,
Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in
Stockholm.